MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/s0169-5002(02)00515-9

Медицинская библиотека · Lung cancer (Amsterdam, Netherlands) · 2003

Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.

Vansteenkiste Johan, Vandebroek Jean, Nackaerts Kris, Dooms Christophe, Galdermans Dany, Bosquée Lionel, Delobbe Alain, Deschepper Koen, Van Kerckhoven Wim, Vandeurzen Kurt, Deman Rene, D'Odemont Jean Pierre, Siemons Luc, Van den Brande Paul, Dams Nancy, Leuven Lung Cancer Group

Клиническое исследованиеСравнительное исследованиеСтатьяРандомизированное исследованиеОбзорПеревод в очереди

Аннотация

BACKGROUND

We previously reported that treatment of patients with symptomatic advanced non-small cell lung cancer with single agent Gemcitabine (GEM) resulted in a superior clinical-benefit response rate (RR) compared to cisplatin-based combination chemotherapy. We now report the detailed individual symptom control analysis, and the influence of cisplatin-use, age, performance status (PS) and duration of treatment.

PATIENTS AND

METHODS

Patients received either GEM (1000 mg/m(2), days 1, 8 and 15) or cisplatin (100 mg/m(2), day 1) plus Vindesine (3 mg/m(2), days 1 and 15) (PV), both every 4 weeks. Scores of 9 symptoms were listed weekly by the patient on visual analogue scales. Improvement of a symptom was defined as 2 consecutive cycles of improvement over baseline.

RESULTS

Baseline symptoms in the 169 patients were well balanced between the 2 arms (84 GEM, 85 PV). Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression. Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis. Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008). Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%. Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.

CONCLUSIONS

Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR. GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms. Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.

Для цитирования: Vansteenkiste Johan, Vandebroek Jean, Nackaerts Kris, Dooms Christophe, Galdermans Dany, Bosquée Lionel, Delobbe Alain, Deschepper Koen, Van Kerckhoven Wim, Vandeurzen Kurt, Deman Rene, D'Odemont Jean Pierre, Siemons Luc, Van den Brande Paul, Dams Nancy, Leuven Lung Cancer Group. Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.. Lung cancer (Amsterdam, Netherlands). 2003. DOI: 10.1016/s0169-5002(02)00515-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.